Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin alpha 1 for Radiation Pneumonitis in Bulky NSCLC
NCT03659578Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2018
- Primary completion
- Sep 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thymosin alpha 1 in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Primary endpoint: Incidence of >=grade 2 radiation pneumonitis at 1 year. Started Aug 2018; status: completed.
02
Drugs
thymosin alpha 1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03659578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03659578.